Boston University School of Public Health news release
A study, published in The Lancet Respiratory Medicine, found that the duration of protection provided by antibiotics that prevent TB infection from developing into active TB disease differs based on countries’ TB disease prevalence.
The study found that the TB preventive treatment (TPT) offered strong protection during the first 12-24 months across settings with all levels of TB burden. In medium- and low-burden settings, this protection lasted for at least 8 and 13 years, respectively, and there was no significant difference in long-term TB disease risk between people who did and did not complete the full course of medication.
However, in high-burden settings, the initial protection achieved from TPT began waning after just one year of taking the medication. Officials in high-burden countries should consider providing this treatment with other protective interventions to achieve the global target of eliminating almost all new TB infections and deaths by 2035.
Read the full news release here.
For more TB updates, check out the TB CAB Weekly Newsletter (Issue #24, 20 September 2026).
The newsletter is brought to you by the Global TB Community Advisory Board (TB CAB) with the support of Treatment Action Group (TAG) and the European AIDS Treatment Group (EATG). Subscribe to the newsletter here.
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.